Chemomab Therapeutics Ltd. appointed Dr. Dale Pfost as new CEO

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


(c) Appointment of Chief Executive Officer


On September 2, 2021, Chemomab Therapeutics Ltd. (the "Company") announced the appointment of Dr. Dale Pfost as Chief Executive Officer of the Company. The effectiveness of Dr. Pfost's appointment is subject to the approval of Dr. Pfost's compensation terms by the shareholders of the Company. Dr. Pfost will replace Dr. Adi Mor, who will step down from her role as Chief Executive Officer, effective as of the appointment of Dr. Pfost, and who will continue to be employed by the Company as Chief Scientific Officer where she will oversee scientific strategy and R&D operations. Dr. Mor will also continue to serve as a Board member.


In connection with Dr. Pfost's appointment as Chief Executive Officer, the Company and Dr. Pfost entered into an executive employment agreement that will be subject to shareholder approval, in accordance with the requirements of the Israeli Companies Law, 5759-1999.


In addition to Dr. Pfost's prospective service as the Chief Executive Officer of the Company, he is also expected to be appointed to the Company's board of directors.


The biographical information for Dr. Pfost appears below:


Dr. Dale Pfost has 35 years of experience as an entrepreneur, investor and business executive. Since 2019, Dr. Pfost has served as Chief Executive Officer and Chairman of the Board of Lodo Therapeutics Corporation. From 2009 until 2019, Dr. Pfost served in a variety of roles at Microbiome Therapeutics, LLC, a company which he co-founded, including as a board member and Chief Executive Officer from 2009 until 2010 and again from 2016 until 2019. From 2010 until 2019, he served as a General Partner at Advent Life Sciences. From 2013 until 2017, Dr. Pfost served in a variety of roles at Vestagen Protective Technologies, including Chairman, Executive Chairman from 2013 until 2017, and Chief Executive Officer from 2015 until 2016. Prior to that, Dr. Pfost held various executive positions at the following companies: Chief Executive Officer at Receptor Biologix Inc. (from 2008 until 2009), President, Chief Executive Officer and Chairman at Acuity Pharmaceuticals, Inc. (from 2003 until 2007), President, Chief Executive Officer and Chairman at Orchid Biosciences, Inc. (from 1996 until 2002), President, Chief Executive Officer and Managing Director at Oxford Glycosciences Ltd. (from 1988 until 1996) and Director of Robotics and Automated Chemistry Systems at Smithkline Beckman from 1984 until 1988. In addition to the foregoing, Dr. Pfost has served on the board of directors of several companies, including Bioelectronica Corp., AxoSim, Inc., JMB Companies LLC, Aura Bioscience, Louisiana BIO and CN Creative. Dr. Pfost earned his BS from the University of California, Santa Barbara, and a PhD in physics from Brown University.


Other than that which is disclosed herein, there are no arrangements or understandings between Dr. Pfost and any other persons pursuant to which he was appointed to serve as Chief Executive Officer or as a Class III director and there are no family relationships between Dr. Pfost and any director or executive officer of the Company. Dr. Pfost has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.